$page_title
VENTIPULMIN® SYRUP
Ventipulmin Syrup (clenbuterol hydrochloride) is indicated for management of horses affected with airway obstruction, such as chronic obstructive pulmonary disease (COPD).
VENTIPULMIN® SYRUP

   
 

Description

Ventipulmin® Syrup is a colorless, palatable syrup. Clenbuterol (4-amino-alpha-((tert-butylamino) methyl)-3,5-dichlorobenzyl alcohol hydrochloride), a beta-2-adrenergic agonist, provides bronchodilating properties with minimum effect on the cardiovascular system.


Features

Only FDA-approved solution for reversible respiratory problems.

Treat-to-effect dose schedule provides optimum level of treatment.

Duration of effect from 6 to 8 hours.

Colorless, palatable syrup provides for easy oral administration.


Benefits

Relieves reversible bronchospasm arising from a variety of respiratory conditions.

Increases mucous secretions for improved airway resistance.

Improves mucociliary transport by decreasing thickness of mucous.


Advantages

Only FDA-approved treatment to relieve reversible bronchospasm from respiratory conditions such as allergy induced respiratory distress, small airway disease or chronic obstructive pulmonary disease (COPD).


Dosage & Administration

Remove safety cap and seal; replace with enclosed dispensing cap. Connect syringe (without needle) to dispensing tip and draw out appropriate volume of Ventipulmin® Syrup (clenbuterol hydrochloride). Administer to horse orally twice a day (b.i.d.). Initial dose is 0.5 mL/100 lbs body weight (0.8 mcg/kg) twice daily. See package insert for complete dosage schedule. Recommended duration of treatment at effective dose is 30 days. At end of 30-day treatment period, drug should be withdrawn to determine recurrence of signs. If signs return, repeat 30-day treatment regimen.


Precautions

Store at controlled room temperature (15-30°C) 59-86°F. Avoid freezing. The safety cap should be placed on the bottle when not in use. Ventipulmin Syrup should not be used in pregnant mares near term or in horses suspected of having cardiovascular impairment.


Uses

Ventipulmin Syrup (clenbuterol hydrochloride) is indicated for management of horses affected with airway obstruction, such as chronic obstructive pulmonary disease (COPD).


Warning

This product is not for human use or for use in animals intended for food. Federal (U.S.A.) law prohibits extralabel use of this drug in food animals. Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian. The reproduction effect in breeding stallions and brood mares has not been determined. Treatment starting with dosages higher than initial dose is not recommended. Keep out of reach of children. In case of accidental ingestion, contact a physician immediately. Clenbuterol, like other beta adrenergic agonists, can produce significant cardiovascular effects in some people as evidenced by elevated pulse rate, blood pressure changes and/or ECG changes.


Highlights

Only FDA-approved solution to relieve reversible bronchospasm.

Six to eight hour duration of effect.

Treat-to-effect dose schedule.

Colorless, palatable, oral syrup.



 
 

Packaging Options (top)

 
 
Product Name
Code
Unit
Size
Case
Size

Case
Weight

Ventipulmin® Syrup

301-715

100 mL

-

-

Ventipulmin® Syrup

301-725

330 mL

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-


 
     
 

Contact Information For VENTIPULMIN® SYRUP (top)

 
 

Boehringer Ingelheim Vetmedica, Inc.
2621 North Belt Highway
St. Joseph, MO 64506
800-821-7467 Information
800-325-9167 Sales
816-236-2717
email: techservices-ca@bi-vetmedica.com
internet: http://www.bi-vetmedica.com

 
     
 

General Product Information Documents (top)

 
 
Product Information Documents

File Type

VENTIPULMIN® SYRUP MSDS Sheet
VENTIPULMIN® SYRUP Detail Sheet
VENTIPULMIN® SYRUP Product Label
VENTIPULMIN® SYRUP Product Image Large
VENTIPULMIN® SYRUP Product Image Medium
VENTIPULMIN® SYRUP Product Image Small

 
 

Product Image for VENTIPULMIN® SYRUP (top)

 
 
Ventipulmin Syrup (clenbuterol hydrochloride) is indicated for management of horses affected with airway obstruction, such as chronic obstructive pulmonary disease (COPD).